Shanghai Bio-heart Biological TechnologyLtd. 

Shanghai Bio-heart Biological Technology Co., Ltd., an interventional cardiovascular device company, focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension in the People's Republic of China. Its BRS products include Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Bioheart Ultra, a BRS product for coronary artery disease featuring an ultra-thin strut; and Bio-Leap, a BRS system for below-the-knee peripheral artery disease. The company's RDN products comprise Iberis 2nd, a multi-electrode RDN product candidate. It is also advancing the development of its balloon catheter product candidates, including balloon dilatation catheters and non-compliant balloon dilatation catheters, as well as impulse balloon dilatation catheters for the treatment of coronary artery calcification, peripheral vascular calcification, and aortic valve calcification. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.